Skip to content
10-Q

Quarterly Report

Edesa Biotech, Inc. EDSA

0001171843-26-000812

← back to feed
Filed
Feb 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Feb 12, 2026 8.35M sh
Operating Cash Flow Q1 2026 · Dec 31, 2025 −$2.09M
Operating Cash Flow Q1 2026 · Dec 31, 2024 −$1.52M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $12.1M
Stockholders Equity Q1 2026 · Dec 31, 2025 $13.95M
Stockholders Equity Q1 2026 · Sep 30, 2025 $12.45M
Stockholders Equity Q1 2026 · Dec 31, 2024 $2.26M
Stockholders Equity Q1 2026 · Sep 30, 2024 $1.98M
Current Liabilities Q1 2026 · Dec 31, 2025 $756.16K
Current Liabilities Q1 2026 · Sep 30, 2025 $1.08M
Current Assets Q1 2026 · Dec 31, 2025 $12.72M
Current Assets Q1 2026 · Sep 30, 2025 $11.51M
Total Assets Q1 2026 · Dec 31, 2025 $14.71M
Total Assets Q1 2026 · Sep 30, 2025 $13.53M
Eps Basic Q1 2026 · Dec 31, 2025 −$0.28
Eps Basic Q1 2026 · Dec 31, 2024 −$0.48
Sga Expense Q1 2026 · Dec 31, 2025 $1.22M
Sga Expense Q1 2026 · Dec 31, 2024 $878.87K
Rd Expense Q1 2026 · Dec 31, 2025 $1.12M
Rd Expense Q1 2026 · Dec 31, 2024 $1.02M
Net Income Q1 2026 · Dec 31, 2025 −$2.25M
Net Income Q1 2026 · Dec 31, 2024 −$1.62M
Operating Income Q1 2026 · Dec 31, 2025 −$2.34M
Operating Income Q1 2026 · Dec 31, 2024 −$1.9M